Test ID: L3AFP
Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum
NY State Approved 
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Useful For Suggests clinical disorders or settings where the test may be helpful
Distinguishing between hepatocellular carcinoma and chronic liver disease
Monitoring individuals with hepatic cirrhosis from any etiology for progression to hepatocellular carcinoma
Surveillance for development of hepatocellular carcinoma in individuals with a positive family history of hepatic cancer
Surveillance for development of hepatocellular carcinoma in individuals within specific ethnic and gender groups who do not have hepatic cirrhosis, but have a confirmed diagnosis of chronic infection by hepatitis B acquired early in life including:
-African males above the age of 20
-Asian males above the age of 40
-Asian females above the age of 50
Method Name A short description of the method used to perform the test
Isotachophoresis with Laser-Induced Fluorescence
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
AFP-L3% and Total AFP, S
External
link
PDF
document
Excel
document
Word
document